Why Blood Cancer Isn’t Like Other Cancers

Gloved hand holding a blood sample tube in a lab rack — Photo: Roman Zaiets / Shutterstock

Leukemia does not act like the tumors most people picture when they hear the word cancer, and that difference is changing how doctors fight it.

Quick Take

Leukemia is a blood cancer, not a solid tumor, so doctors treat it with a different playbook.
Mayo Clinic doctors test leukemia cells for genetic changes before picking a treatment plan.
Targeted drugs and immune-based therapies can sometimes replace or reduce traditional chemotherapy.
This gene-guided approach has worked especially well in certain leukemia types for years.

Why Leukemia Plays By Different Rules

Solid tumors form lumps doctors can biopsy, image, and sometimes cut out. Leukemia is different. It starts when blood cells pick up mutations in their genetic material and multiply out of control, flooding the bloodstream and bone marrow instead of forming a single mass. That spread-out nature means surgery rarely helps. Doctors instead lean on drugs and, increasingly, on reading the cancer’s genetic code first.

Genetic Testing Now Drives The Treatment Plan

Doctor Arana Yi at Mayo Clinic explains that research is helping physicians spot the genetic changes driving a patient’s leukemia. That information shapes what comes next. “This allows us to use targeted medicines, immune-based therapies, sometimes with less traditional chemotherapy or chemo-free regimen,” she says. The shift moves treatment away from one-size-fits-all chemo toward a plan built around each patient’s specific cancer cells.

Mayo Clinic’s own patient guidance backs this up in plain terms. Leukemia cells get tested to see if targeted therapy could help, because these treatments zero in on specific abnormalities inside cancer cells and can cause them to die once those weak points are blocked. That is a meaningfully different strategy than broad chemotherapy, which attacks fast-dividing cells everywhere in the body, healthy or not.

Why Type And Subtype Matter So Much

Not all leukemia is the same, and Mayo Clinic stresses that getting the exact diagnosis right changes everything downstream. Molecular testing looks for genetic changes because some therapies only work on certain markers, and outcomes can swing widely between subtypes. Matching the right drug to the right mutation is now considered essential, not optional, for patients hoping for the best shot at remission.

Acute myeloid leukemia shows how far this has come. Doctor Mrinal Patnaik has noted that almost everyone with this cancer carries some genetic abnormality in their cells, and understanding those abnormalities has driven major treatment advances over the last five to seven years. Mayo Clinic Laboratories now run multi-gene panels checking for specific mutations tied to acute myeloid leukemia at diagnosis, helping guide which therapy a patient should get.

A Track Record That Predates The Hype

Blood cancers were doing precision medicine before it was a buzzword. Chronic myelogenous leukemia became the field’s proof of concept decades ago, when a drug targeting its exact genetic driver transformed survival rates in a way oncologists still cite today. Reviews of hematologic cancers note genetic testing has been part of routine care for decades to guide classification, prognosis, and treatment choice.

Chronic lymphocytic leukemia follows the same pattern. Care teams commonly run a fluorescence in situ hybridization panel to check for genetic changes tied to prognosis and drug selection. Doctors have learned that cancer happens when cells pick up DNA changes, and lab tests can pinpoint exactly which changes are present in a given patient’s leukemia cells.

Solid Tumors Still Lag Behind This Model

Solid cancers have not caught up to this level of precision, and that gap matters for the bigger picture. Cell-based immune therapies that work well against blood cancers have struggled in solid tumors, partly because those tumors hide behind a suppressive environment and lack easy, accessible targets. Researchers openly acknowledge that targeted agents in solid tumors have not yet matched the results imatinib delivered for leukemia patients.

None of this means every leukemia patient gets a chemo-free path, and doctors still tailor plans case by case based on subtype, stage, and how a patient responds. But the direction is clear. Genetic testing at diagnosis, not a guessing game, increasingly decides which drugs a leukemia patient receives, and that approach keeps expanding as researchers identify more targetable mutations.